Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 24, 2007 Brian Lawler	Is the Worst Over for QLT? The biopharma announces another dismal quarter of declining sales for its top compound.
The Motley Fool February 26, 2007 Brian Lawler	Is QLT the Comeback Kid? The Canadian drugmaker updates investors on its outlook for 2007.
The Motley Fool July 5, 2006 Brian Lawler	Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid.
The Motley Fool July 17, 2007 Brian Lawler	QLT Stays the Course Sales of QLT's Visudyne, a drug to treat macular degeneration, continue to plummet due to competition. QLT plans to try to resuscitate.
The Motley Fool October 26, 2006 Brian Lawler	QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note.
The Motley Fool January 22, 2007 Brian Lawler	QLT's Sagging Sales The drug developer's macular degeneration treatment has seen declining sales. And as sales fall, so too does the percent of profits that QLT keeps. Investors, take note.
The Motley Fool March 31, 2008 Brian Lawler	A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration.
The Motley Fool November 29, 2007 Brian Lawler	QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale.
The Motley Fool October 29, 2007 Brian Lawler	QLT in a Rut or Ready for a Comeback? QLT updates investors on its top drugs.
The Motley Fool March 18, 2008 Brian Lawler	QLT's Blemished Aczone Clears Up A more lenient label from the FDA is good news for this drugmaker.
The Motley Fool August 31, 2007 Brian Lawler	QLT Gets Reformulated Drug developer QLT announced that an EU approval will open new markets for the cancer drug that could edge out the competition by lowering overall medical costs.
The Motley Fool April 25, 2005 Charly Travers	Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around?
The Motley Fool September 12, 2006 Brian Lawler	Those Buybacks at QLT Is the biopharmaceutical repurchasing shares to make itself more attractive for an acquisition? Investors, take note.
The Motley Fool June 10, 2008 Brian Lawler	Allergan's Unblemished Deal Acquiring a niche acne drug from QLT provides clarity for both companies.
The Motley Fool April 28, 2005 Charly Travers	QLT's a Clutch Performer Pharma continues to deliver growth through difficult times.
The Motley Fool August 31, 2004 Charly Travers	Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one.
The Motley Fool January 21, 2005 Charly Travers	Seeing the Value in QLT A narrow-minded market could be creating a great drug value.
The Motley Fool March 29, 2005 Charly Travers	A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT.
The Motley Fool June 15, 2004 Charly Travers	QLT Swallows Atrix Atrix Laboratories has been purchased by Canadian drug company QLT. For Atrix shareholders, the timing of this deal must be incredibly frustrating.
The Motley Fool February 23, 2005 Charly Travers	QLT Is Still a Value The market's concerns mean this Canadian drug company is being offered up at a great price.
The Motley Fool August 21, 2008 Brian Lawler	Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment.
The Motley Fool July 29, 2005 Richard Gibbons	Share Buybacks Aren't All Equal In the right circumstances -- when a company has excess capital and undervalued shares -- share repurchases are great for shareholders. But if the company is repurchasing overvalued shares, the buyback can actually be a sign of poor management.
The Motley Fool October 28, 2008 Rich Duprey	Don't Buy the Buyback Hype Are share buybacks little more than a tool for management to massage earnings? As for the benefit to individual shareholders, is it all it's cracked up to be?
The Motley Fool July 3, 2007 Rich Smith	Steel Dynamics Gets Busy There is no value prop here for shareholders. Rather than a buyback, a better move for Steel Dynamics would be to pay down a bit of its debt load.
The Motley Fool May 24, 2005 Charly Travers	Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note.
The Motley Fool March 6, 2008 Rich Smith	Juniper's Billion-Buck Buyback But who will reap the rewards?
The Motley Fool October 2, 2007 Brian Orelli	Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data.
The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
The Motley Fool December 7, 2006 Seth Jayson	Bad Advice on Buybacks The point of a buyback is not to "move" the stock -- not over the short term. The point of a buyback is to increase shareholder value in the long run by giving existing shareholders a bigger cut of future economic benefits.
Entrepreneur October 2006 C.J. Prince	Buyback Bonanza Big companies with excess cash have jumped on the buyback bandwagon and are milking it for all it's worth. Should you do the same?
The Motley Fool February 11, 2005 Stephen D. Simpson	For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant.
The Motley Fool October 5, 2007 Rich Duprey	Pennies on the Dollar Tree Management at the discounter announces a $500 million share buyback; investors ought to ask themselves: Is Dollar Tree a good buy now?
InternetNews August 18, 2006 Ed Sutherland	Microsoft Buys Back Billions in Stock Microsoft said it will repurchase $16.2 billion shares of additional stock, expanding the buyback program announced in July to $36.2 billion.
The Motley Fool August 16, 2005 Rich Smith	Central Parking Seeks an Exit By simultaneously trying to boost its stock price with a costly buyback plan, this garage operator is trying to go a bridge too far.
The Motley Fool December 8, 2004 Rich Duprey	Buybacks Can Predict Profits Use management's signal flag of an undervalued stock to make market-beating profits.
The Motley Fool January 5, 2005 Rich Duprey	Sharks Don't Go Blind Shark liver oil shows promise in treatment of age-related macular degeneration. Genaera Corp. though leading this interesting investigation, is not profitable, racking up some significant losses over the years.
The Motley Fool January 11, 2011 Esterhuizen & Sellitti	Undervalued Companies Buying Back Their Own Stock How do you know when a stock is undervalued?
The Motley Fool January 26, 2011 Matt Koppenheffer	That Nagging Cash Pile at Apple A look at share buybacks and whether Apple should unleash its massive cash hoard.
The Motley Fool August 25, 2009 Brian Orelli	That's How You Want to Spend Investors' Money? A high-growth buyback? Really? On the surface, the buyback of Illumina shares looks like a pretty poor use of capital, but in truth, the move might not be that bad for investors.
The Motley Fool October 27, 2011 Alex Dumortier	Don't Buy Into People's United's Buyback People's United's new buyback program doesn't mean you should buy.